Loading company…
Santersus develops a blood purification device designed to remove neutrophil extracellular traps.
Founded in 2017 and based in Zurich, Santersus develops therapeutic apheresis products, including the NucleoCapture device. The device is designed to remove neutrophil extracellular traps from blood and is being developed for conditions including sepsis and lupus. In December 2025, Santersus raised undisclosed Series A funding led by Norcliffe Capital, with Terumo Ventures participating, to advance clinical trials and pipeline programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in